ZimVie Stock News

ZimVie (ZIMV) Q2 EPS Doubles to $0.26

Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per share Net Sales from Continuing Operations of $116.7 million Net Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA [1] from Continuing Operations of $17.5 million; Adjusted EBITDA [1] margin of 15.0% GAAP diluted EPS from Continuing Operations of $(0.14) and ad...

PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025.

PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Under the terms of the proposed transaction, shareholders of ZimVie will receive $19.00 in cash for each share of ZimVie that they own. KSF...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

ZimVie shares catapulted by triple digits Monday after the dental implant maker agreed to a $730 million takeover deal.

MILWAUKEE , July 21, 2025 /PRNewswire/ -- The Ademi Firm is investigating ZimVie (NASDAQ: ZIMV) for possible breaches of fiduciary duty and other violations of law in its transaction with ARCHIMED. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.